Cargando…

Computational Insights into Novel Inhibitor N-(3-(tert-Butylcarbamoyl)-4-methoxyphenyl)-indole and Ingliforib Specific against GP Isoenzyme Dimers Interaction Mechanism

The high conservation of the three subtypes of glycogen phosphorylase (GP) presents significant challenges for specific inhibitor studies targeting GP. Our prior screening revealed that compound 1 exhibited unequal inhibitory activity against the three GP subtypes, with a noticeable effect against b...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Youde, Li, Shuai, Yan, Zhiwei, Zhang, Liying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10343391/
https://www.ncbi.nlm.nih.gov/pubmed/37446571
http://dx.doi.org/10.3390/molecules28134909
_version_ 1785072725991096320
author Wang, Youde
Li, Shuai
Yan, Zhiwei
Zhang, Liying
author_facet Wang, Youde
Li, Shuai
Yan, Zhiwei
Zhang, Liying
author_sort Wang, Youde
collection PubMed
description The high conservation of the three subtypes of glycogen phosphorylase (GP) presents significant challenges for specific inhibitor studies targeting GP. Our prior screening revealed that compound 1 exhibited unequal inhibitory activity against the three GP subtypes, with a noticeable effect against brain GP (PYGB). The commercially available ingliforib demonstrated potent inhibitory activity specifically against liver GP (PYGL). To guide the further design and screening of high-specificity inhibitors, the possible reasons for the differential inhibitory activity of two compounds against different GP subtypes were analyzed, with ingliforib as a reference, through molecular docking and molecular dynamics simulations. Initially, the study predicted the binding modes of ligands with the three GP receptor subtypes using molecular docking. Subsequently, this was validated by molecular dynamics experiments, and possible amino acid residues that had important interactions were explored. The strong correlation between the calculated interaction free energies and experimental inhibitory activity implied the reasonable binding conformations of the compounds. These findings offer insight into the different inhibitory activity of compound 1 and ingliforib against all three GP subtypes and provide guidance for the design of specific target molecules that regulate subtype selectivity.
format Online
Article
Text
id pubmed-10343391
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103433912023-07-14 Computational Insights into Novel Inhibitor N-(3-(tert-Butylcarbamoyl)-4-methoxyphenyl)-indole and Ingliforib Specific against GP Isoenzyme Dimers Interaction Mechanism Wang, Youde Li, Shuai Yan, Zhiwei Zhang, Liying Molecules Article The high conservation of the three subtypes of glycogen phosphorylase (GP) presents significant challenges for specific inhibitor studies targeting GP. Our prior screening revealed that compound 1 exhibited unequal inhibitory activity against the three GP subtypes, with a noticeable effect against brain GP (PYGB). The commercially available ingliforib demonstrated potent inhibitory activity specifically against liver GP (PYGL). To guide the further design and screening of high-specificity inhibitors, the possible reasons for the differential inhibitory activity of two compounds against different GP subtypes were analyzed, with ingliforib as a reference, through molecular docking and molecular dynamics simulations. Initially, the study predicted the binding modes of ligands with the three GP receptor subtypes using molecular docking. Subsequently, this was validated by molecular dynamics experiments, and possible amino acid residues that had important interactions were explored. The strong correlation between the calculated interaction free energies and experimental inhibitory activity implied the reasonable binding conformations of the compounds. These findings offer insight into the different inhibitory activity of compound 1 and ingliforib against all three GP subtypes and provide guidance for the design of specific target molecules that regulate subtype selectivity. MDPI 2023-06-22 /pmc/articles/PMC10343391/ /pubmed/37446571 http://dx.doi.org/10.3390/molecules28134909 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wang, Youde
Li, Shuai
Yan, Zhiwei
Zhang, Liying
Computational Insights into Novel Inhibitor N-(3-(tert-Butylcarbamoyl)-4-methoxyphenyl)-indole and Ingliforib Specific against GP Isoenzyme Dimers Interaction Mechanism
title Computational Insights into Novel Inhibitor N-(3-(tert-Butylcarbamoyl)-4-methoxyphenyl)-indole and Ingliforib Specific against GP Isoenzyme Dimers Interaction Mechanism
title_full Computational Insights into Novel Inhibitor N-(3-(tert-Butylcarbamoyl)-4-methoxyphenyl)-indole and Ingliforib Specific against GP Isoenzyme Dimers Interaction Mechanism
title_fullStr Computational Insights into Novel Inhibitor N-(3-(tert-Butylcarbamoyl)-4-methoxyphenyl)-indole and Ingliforib Specific against GP Isoenzyme Dimers Interaction Mechanism
title_full_unstemmed Computational Insights into Novel Inhibitor N-(3-(tert-Butylcarbamoyl)-4-methoxyphenyl)-indole and Ingliforib Specific against GP Isoenzyme Dimers Interaction Mechanism
title_short Computational Insights into Novel Inhibitor N-(3-(tert-Butylcarbamoyl)-4-methoxyphenyl)-indole and Ingliforib Specific against GP Isoenzyme Dimers Interaction Mechanism
title_sort computational insights into novel inhibitor n-(3-(tert-butylcarbamoyl)-4-methoxyphenyl)-indole and ingliforib specific against gp isoenzyme dimers interaction mechanism
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10343391/
https://www.ncbi.nlm.nih.gov/pubmed/37446571
http://dx.doi.org/10.3390/molecules28134909
work_keys_str_mv AT wangyoude computationalinsightsintonovelinhibitorn3tertbutylcarbamoyl4methoxyphenylindoleandingliforibspecificagainstgpisoenzymedimersinteractionmechanism
AT lishuai computationalinsightsintonovelinhibitorn3tertbutylcarbamoyl4methoxyphenylindoleandingliforibspecificagainstgpisoenzymedimersinteractionmechanism
AT yanzhiwei computationalinsightsintonovelinhibitorn3tertbutylcarbamoyl4methoxyphenylindoleandingliforibspecificagainstgpisoenzymedimersinteractionmechanism
AT zhangliying computationalinsightsintonovelinhibitorn3tertbutylcarbamoyl4methoxyphenylindoleandingliforibspecificagainstgpisoenzymedimersinteractionmechanism